

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

RELEVANT EVENT

Grifols has acquired an additional 40% equity stake in Kiro Grifols, S.L. ("**Kiro Grifols**") (formerly "Kiro Robotics, S.L.") for a purchase price of EUR 12.8m. In September 2014 Grifols subscribed to a capital increase by virtue of which Grifols acquired 50% of Kiro Grifols' economic and voting rights. With this new acquisition, Grifols has reached a 90% stake in the equity of Kiro Grifols. The remaining 10% will continue to be held by Socios Fundadores Kiro, S.L., a company wholly owned by cooperatives of the Mondragon Corporation.

Kiro Grifols is a technological-based company focused on the development of machinery and equipment designed to automate hospital processes. Kiro Oncology system prepares automated intravenous medication for chemotherapy treatments in hospital pharmacies, thus minimizing the margin of error in the preparation of medication and the risk to health professionals.

In Barcelona, on 24 July 2017

Nuria Martín Barnés
Secretary to the Board of Directors